Navigation Links
Lilly's John Lechleiter Becomes PhRMA Board Chairman; Robert J. Hugin, Ian Read Assume New Posts
Date:4/13/2012

BOSTON, April 13, 2012 /PRNewswire-USNewswire/ -- John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Celgene Corporation President, CEO, and Chairman Robert J. Hugin as chairman-elect of the PhRMA Board of Directors, and Ian C. Read, president and CEO of Pfizer, Inc., as board treasurer. 

(Logo: http://photos.prnewswire.com/prnh/20091027/PHRMALOGO )
 
Dr. Lechleiter succeeds Christopher Viehbacher, CEO of Sanofi, as PhRMA's chairman. 
 
"Chris has been indispensable to PhRMA on many fronts, providing invaluable leadership as the industry navigates the evolving policy and regulatory landscapes essential to continued innovation while always putting patients first," said PhRMA President and CEO John J. Castellani. "As Dr. Lechleiter assumes the chairman role, we can all feel comfort knowing that the patient-centered approaches we utilize in all our advocacy efforts will continue to be central to our mission of advancing innovation in the U.S and worldwide.  It is an honor to work closely with these visionary, passionate leaders of our sector." 

Dr. Lechleiter has served as chairman, president, and CEO of Lilly since 2008. He became president and chief operating officer of Lilly in 2005, when he joined the company's board of directors. His career at Lilly began in 1979 as a senior organic chemist in process research and development -- a department he later led in 1982. He was named executive vice president for pharmaceutical products and corporate development in 2001. In 2004, he became Lilly's executive vice president for pharmaceutical operations.

"I'm honored to lead PhRMA during this very important time in the history of our industry," Dr. Lechleiter said. "PhRMA member companies play an incredibly important role in the delivery of high-quality, cost-effective health care for our citizens. Continued progress against diseases like Alzheimer's disease, cancer, and diabetes requires policies that enable medical innovation to thrive. I look forward to the opportunity to advance these important conversations at an industry level." 

Mr. Hugin became CEO of Celgene Corporation in June of 2010 having served as president and COO since May 2006. In June 2011, the Board of Directors elected Mr. Hugin Chairman. He was instrumental in the strategic growth of the company overseeing the expansion of Celgene from a US-based biopharmaceutical company to a global company with operations in more than 50 countries located in the Americas, Europe, Japan and the Asia-Pacific region. He joined Celgene as senior vice president and chief financial officer in June 1999 and was elected to the Board of Directors in December 2001.  

"Advances in healthcare will continue to be a critical source of breakthroughs extending and improving patients' lives, reducing overall healthcare costs and driving economic growth," Mr. Hugin said. "Through PhRMA, America's biopharmaceutical companies work together with government, physicians, health care payers and patient advocates to build supportive policies for biomedical innovation, designed to deliver disease-altering treatments for patients through transformational science."

Mr. Read was named chairman and CEO of Pfizer in December 2010. He began his career with Pfizer in 1978 as an operational auditor. Mr. Read worked in Latin America through 1995, holding positions in a number of Pfizer's international operations. In 1996, he was appointed president of Pfizer's International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became executive vice president, Europe in 2000, and was named a corporate vice president in 2001. In 2006, he became senior vice president, Pfizer, and group president of the Worldwide Biopharmaceutical Businesses. 

"This industry works at the heart of the United States' innovative core, and it will help power the nation's continued economic resurgence," Read said. "As industry and the country grow stronger, so will the benefits for patients that need and deserve them."

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $49.5 billion in 2011 in discovering and developing new medicines.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: http://www.innovation.org
For information on the Partnership for Prescription Assistance, visit: http://www.pparx.org
For information on ensuring the flow of medicines during public health emergencies, visit http://www.rxresponse.org

 


'/>"/>
SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lilly CEO Lechleiter Calls for Repair of the Engine of Biopharma Innovation
2. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
3. Lilly CEO Lechleiter Outlines Opportunities for Improved Health and Economic Growth in Asia-Pacific Region
4. Surgex(TM) Becomes the First and Only BSCG (Banned Substance Control Group) Certified Product Which is Clinically Proven Effective in Sports Recovery and Performance
5. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
6. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
7. CTMM Becomes One of the Worlds Largest Public-Private Partnerships in Translational Medical Research
8. Fora Care Group Becomes Pioneering Educational Member of the International Society of Vascular Health
9. US Oncology Foundation Becomes Life Beyond Cancer Foundation
10. Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
11. Triage Wireless, Inc. Becomes Sotera Wireless, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... , June 23, 2016  In a startling report released ... failing their residents by lacking a comprehensive, proven plan to eliminate ... a definitive ranking of how states are tackling the worst drug ... only four states – Kentucky , ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):